Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of QUB HCT116 sensitive and resistant colorectal cancer time series
HCT116 parental, HCT116 5-FU resistant and HCT116 oxaliplatin resistant cells have been transiently treated with with their respective drug (5-FU or oxaliplatin) for 0, 6 12 or 24h in 3 independent experiments.
ORGANISM(S): Homo sapiens 
2006-01-01 | E-MEXP-390 | biostudies-arrayexpress
UnknownQuality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.
Not available
S-EPMC4879707 | biostudies-literature
UnknownTreatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
Not available
S-EPMC9874879 | biostudies-literature
UnknownUpdate on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.
Not available
S-EPMC3286387 | biostudies-literature
UnknownThe benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
Not available
S-EPMC3386495 | biostudies-literature
UnknownEffect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Not available
S-EPMC7556338 | biostudies-literature
Sort   by:  
 Page size